Compare AUID & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUID | HCWB |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 14.8M |
| IPO Year | 2014 | 2021 |
| Metric | AUID | HCWB |
|---|---|---|
| Price | $0.89 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 236.6K | ★ 459.2K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | N/A |
| EPS | N/A | ★ 0.37 |
| Revenue | $2,040,660.00 | ★ $4,099,750.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.35 |
| Revenue Growth | ★ 130.20 | N/A |
| 52 Week Low | $0.76 | $0.25 |
| 52 Week High | $4.70 | $7.35 |
| Indicator | AUID | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 34.35 | 60.85 |
| Support Level | N/A | $0.37 |
| Resistance Level | $1.39 | $5.61 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 22.60 | 18.35 |
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.